Detalhe da pesquisa
1.
Rational design of a new antibiotic class for drug-resistant infections.
Nature
; 597(7878): 698-702, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34526714
2.
In vivo dose response and efficacy of the ß-lactamase inhibitor, durlobactam, in combination with sulbactam against the Acinetobacter baumannii-calcoaceticus complex.
Antimicrob Agents Chemother
; 68(1): e0080023, 2024 Jan 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38092671
3.
I n vitro pharmacokinetics/pharmacodynamics of the ß-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complex.
Antimicrob Agents Chemother
; 68(1): e0031223, 2024 Jan 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38092676
4.
N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.
Bioorg Med Chem
; 28(24): 115826, 2020 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33160146
5.
Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
J Antimicrob Chemother
; 72(10): 2796-2803, 2017 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29091195
6.
Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy.
Antimicrob Agents Chemother
; 59(12): 7743-52, 2015 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-26438502
7.
Pharmacokinetics of the natural antibiotic negamycin.
Xenobiotica
; 45(7): 625-33, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-25733027
8.
Use of uptake intrinsic clearance from attached rat hepatocytes to predict hepatic clearance for poorly permeable compounds.
Xenobiotica
; 42(9): 830-40, 2012 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-22439758
9.
Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance.
Drug Metab Dispos
; 38(2): 223-31, 2010 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-19875499
10.
Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the ß-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282.
ACS Infect Dis
; 6(6): 1378-1388, 2020 06 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32379415
11.
Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine ß-Lactamases.
J Med Chem
; 63(21): 12511-12525, 2020 11 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32658473
12.
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.
Bioorg Med Chem Lett
; 19(22): 6307-12, 2009 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-19819693
13.
Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.
J Med Chem
; 51(10): 2879-82, 2008 May 22.
Artigo
Inglês
| MEDLINE | ID: mdl-18426196
14.
Reversibility of Covalent, Broad-Spectrum Serine ß-Lactamase Inhibition by the Diazabicyclooctenone ETX2514.
ACS Infect Dis
; 3(11): 833-844, 2017 11 10.
Artigo
Inglês
| MEDLINE | ID: mdl-28835096
15.
Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model.
J Med Chem
; 58(5): 2195-205, 2015 Mar 12.
Artigo
Inglês
| MEDLINE | ID: mdl-25658376
16.
Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.
J Med Chem
; 54(13): 4427-45, 2011 Jul 14.
Artigo
Inglês
| MEDLINE | ID: mdl-21634377
17.
Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Cancer Res
; 68(16): 6680-7, 2008 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-18701492
18.
Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).
J Med Chem
; 51(13): 3688-91, 2008 Jul 10.
Artigo
Inglês
| MEDLINE | ID: mdl-18553959